Colonis are happy to announce that Andy Trouton has recently rejoined the team as Managing Director. With over 35 years of experience in the pharmaceutical industry across brands, generics and unlicensed medicines, Andy will be once again guiding the strategic direction of the Colonis team, providing leadership through development and commercialisation of our novel value-added medicine portfolio.
“I’m delighted to be back leading the team at Colonis again after a 3-year break and its incredible to see the progress that has been made in identifying and bringing novel value-added medicines to market. Everyone at Colonis is very excited about being part of this next stage in the development of the business” Andy Trouton, Managing Director
Colonis are also pleased to introduce Derek Lilley as our new National Account Manager. Derek will be overseeing all UK commercial activities and strategy for the Colonis portfolio. He brings 12 years of pharmaceutical experience in the retail and hospital sector, promoting generic and branded generic medicines across numerous therapy areas. Derek will be using this insight to continue the success of our existing portfolio whilst planning for the launch of upcoming Colonis value-added medicines.
To learn more about the Colonis team click here www.colonis.co.uk/about-us/#the-team
GB-CPL-0-022
September 2023